Ixazomib
- Generic Name
- Ixazomib
- Brand Names
- Ninlaro
- Drug Type
- Small Molecule
- Chemical Formula
- C14H19BCl2N2O4
- CAS Number
- 1072833-77-2
- Unique Ingredient Identifier
- 71050168A2
- Background
Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple...
- Indication
Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
- Associated Conditions
- Multiple Myeloma (MM)
- Associated Therapies
- -
Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-12-04
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT03763162
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
- First Posted Date
- 2018-11-21
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT03748953
- Locations
- 🇨🇳
Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
🇨🇳Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
🇨🇳Shanghai Chang Zheng Hospital, Shanghai, Shanghai, China
Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients
- Conditions
- Interventions
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Oncotherapeutics
- Target Recruit Count
- 19
- Registration Number
- NCT03733691
- Locations
- 🇺🇸
James R Berenson, MD, Inc., West Hollywood, California, United States
Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 45
- Registration Number
- NCT03669445
- Locations
- 🇫🇷
CHU Bordeaux, Bordeaux, France
🇫🇷CHU de Dijon, Dijon, France
🇫🇷CHRU de Lille, Lille, France
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- Celgene
- Target Recruit Count
- 381
- Registration Number
- NCT03651128
- Locations
- 🇺🇸
Local Institution - 145, Los Angeles, California, United States
🇺🇸Local Institution - 122, Los Angeles, California, United States
🇺🇸Local Institution - 131, Atlanta, Georgia, United States
Ixazomib Maintenance Study in Patients With AL Amyloidosis
- First Posted Date
- 2018-08-07
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT03618537
- Locations
- 🇺🇸
Memorial Sloan Kettering Nassau, Uniondale, New York, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Ho Sup Lee
- Target Recruit Count
- 98
- Registration Number
- NCT03616782
- Locations
- 🇰🇷
Kosin University Gospel Hospital, Busan, Western, Korea, Republic of
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2020-01-14
- Lead Sponsor
- Takeda
- Registration Number
- NCT03608501
- Locations
- 🇧🇷
Instituto COI de Educacao e Pesquisa, Rio de Janeiro, RJ, Brazil
🇧🇷Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil
🇧🇷Universidade Estadual de Campinas UNICAMP - HEMOCENTRO, Campinas, SP, Brazil
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-07-18
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 46
- Registration Number
- NCT03590652
- Locations
- 🇺🇸
UCSD Moores Cancer Center, La Jolla, California, United States
Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-07-16
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT03587662
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.